Appearance of Strong Transplantation Antigens in Non-Immunogenic Lymphoma Following Drug-Treatment In Vivo

Publisher Website
Google Scholar
Abstract
A chemically [dimethylbenzanthracene] induced lymphosarcoma cell line (LSBM-1) of C57BL/10 (H-2b) [mouse] origin lacks detectable TATA [tumor-associated transplantation antigens] and is scarcely immunogenic for H-2-incompatible congenic recipients. New antigenic specificities, defined as drug-mediated tumor antigen(s) (DMTA), were found in a subline (LBD-1) obtained by in vivo treatment of LSBM-1 with the antineoplastic agent dimethyl-1-triazeno-imidazole-carboxamide (DTIC) over several transplant generations. The presence of detectable TATA apparently is not a prerequisite for the induction of new antigenic specificities (DMTA). This artificial means of induction of TATA opens up new perspectives in cancer immunotherapy.